“With our LNCB74 antibody-drug conjugate program completing cohort 2 in April 2025, we are progressing as planned through the dose escalation portion of the Phase 1 study. We expect to be in a position to initiate backfill cohorts in the second half of the year with 10 active investigator sites, and an additional 3 sites projected to be onboard in May 2025. We plan to provide a proof of concept data readout in the first half of 2026,” said Michael Richman, NextCure’s (NXTC) president and CEO.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NXTC:
- NextCure Updates Presentation on LNCB74 Clinical Trial
- Optimistic Buy Rating for NextCure Driven by Promising Developments in LNCB74 for Endometrial Cancer
- H.C. Wainwright says competitor data builds optimism for NextCure’s LNCB74
- Nextcure Faces Delisting Risk Amid Nasdaq Compliance Struggles
- NextCure Reports 2024 Financials and Strategic Progress